Since the end of 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred in China. In a recent report published in JAMA, 26.1% of 138 coronavirus disease 2019 (COVID-19) patients needed to be admitted to intensive care unit (ICU), of which 61.1% were suffering from acute respiratory distress syndrome (ARDS). The case fatality rate of COVID-19 has been reported about 4.3%([@bib0005]). Until now, no specific treatment has been recommended for COVID-19.

Historical perspective {#sec0005}
======================

Extracorporeal membrane oxygenation (ECMO), which can provide effective respiratory or cardiac support, has been regarded as a rescue therapy for severe ARDS. ECMO therapy during the influenza A (H1N1) pandemic in 2009 appeared to benefit, with ECMO-treated patients with H1N1-related ARDS achieving a mortality of 21%, which greatly increased interest in its use ([@bib0010]). Another cohort study by using ECMO database of patients with H1N1-related ARDS showed that hospital mortality rate was 23.7% for ECMO-referred patients vs 52.5% for non-ECMO-referred patients (RR, 0.45 \[95% CI, 0.26-0.79\]; P = 0.006) when individual matching was used; 24.0% vs 46.7%, respectively (RR, 0.51 \[95% CI, 0.31-0.81\]; P = 0.008) when propensity score matching was used; and 24.0% vs 50.7%, respectively (RR, 0.47 \[95% CI, 0.31-0.72\]; P = 0.001) when GenMatch matching was used. These suggested that for patients with H1N1-related ARDS, ECMO-referred patients were associated with significantly lower hospital mortality compared with matched non-ECMO-referred patients ([@bib0015]). A clinical trial, named as CESAR, was encouraging as well ([@bib0020]). However, EOLIA Clinical Trial showed that 60­day mortality with very severe ARDS patients was not significantly lower, yet was largely reduced in the ECMO group compared with the conventional mechanical ventilation group (35% vs 46%; RR, 0.76 \[95% CI, 0.55-1.04\]; P = 0.09), but there was a 28% crossover to ECMO for failure of conventional mechanical ventilation, suggesting a lack of clinical equipoise ([@bib0025]). Otherwise, a post hoc Bayesian analysis of EOLIA with various assumptions of prior belief and knowledge about ECMO efficacy in ARDS had shown the posterior probability of a mortality reduction with ECMO in the EOLIA trial ([@bib0030]). In 2018, a retrospectively study on middle east respiratory syndrome (MERS) patients with refractory respiratory failure indicated that ECMO should be used as a rescue therapy, and ECMO group was associated with lower mortality in MERS patients with refractory hypoxemia compared with the conventional group (65 *vs* 100%, P = 0.02)([@bib0035]) ([Table 1](#tbl0005){ref-type="table"} ).Table 1Clinical studies of ECMO for respiratory failureTable 1ApplicationPublication timeStudy designOutcomes of ECMOReferenceInfluenza A (H1N1) ARDS2009Observational studyA mortality rate of 21% in the ECMO-treated patients([@bib0010])ARDS (CESAR)2009Multicenter RCT63% (57/90) of patients considered by ECMO survived to 6 months without disability compared with 47% (41/87) of those allocated to conventional management (RR, 0.69; 95% CI 0.05-0.97, p = 0.03)([@bib0020])Influenza A (H1N1) ARDS2011Cohort studyECMO-referred patients was associated with lower mortality compared with match non-ECMO-referred patients([@bib0015])ARDS (EOLIA)2018Multicenter RCT60­day mortality was not significantly lower with ECMO than with a strategy of conventional mechanical ventilation(35% vs 46%, p = 0.09)([@bib0025])MERS2018Retrospective studyECMO use was associated with lower mortality in MERS patients with refractory hypoxemia (65% vs 100%, P = 0.02)([@bib0035])[^2]

Application situation of ECMO for COVID-19 in China {#sec0010}
===================================================

According to the interim guidance formulated by the World Health Organization (WHO), ECMO should be considered as a rescue therapy for COVID-19 with refractory hypoxemia despite lung-protective ventilation ([@bib0040]). However, there is little experience with using ECMO to support SARS-CoV-2-infected patients ([@bib0005], [@bib0045], [@bib0050], [@bib0055], [@bib0060]). Most of studies didn't report the clinical outcomes of ECMO use except for two studies. In the retrospective study conducted by Yang et al., 52 critically ill adult patients were identified with SARS-CoV-2 pneumonia and were admitted to intensive care unit (ICU), among them, 31 patients had died at 28 days. 6 patients were received ECMO, and 5 of them died and 1 patient was still on ECMO at the endpoint ([@bib0045]). Another retrospective study implemented by Guqin et al. included 221 patients with laboratory confirmed SARS-CoV-2 pneumonia, 48 of severe patients developed ARDS, and 10 of them received invasive mechanical ventilation (IMV) and ECMO support. 2 patients had clinical benefits and had been discharged and 3 of them were non-survivors. The rest 5 patients were still on ECMO at the endpoint ([@bib0050]) ([Table 2](#tbl0010){ref-type="table"} ). Given lacking of clinical trial of ECMO on COVID-19, we could not conclude whether SARS-CoV-2-infected patients have benefited from ECMO at this time. But our concern may be settled by the ongoing trials in China (ChiCTR2000030744 and ChiCTR2000029804).Table 2Current clinical uses of ECMO for COVID-19Table 2ApplicationStudy designCases on ECMO (total cases)Outcomes of ECMOReferenceCritically ill patients with SARS-CoV-2 pneumoniaSingle center, retrospective, study6 (52)Five patients died while one patient was still on ECMO at the endpoint([@bib0045])Patients with ARDS caused by SARS-CoV-2Single center, retrospective study10 (221)Two patients were discharged, three patients died, and five patients were still on ECMO at the endpoint([@bib0050])Critically ill patients with SARS-CoV-2 pneumoniaSingle center, retrospective study4 (138)NA([@bib0055])Critically ill patients with SARS-CoV-2 pneumoniaMulticenter retrospective study5 (1099)NA([@bib0060])Critically ill patients with SARS-CoV-2 pneumoniaSingle center prospective study2 (41)NA([@bib0065])[^3]

Indications for the treatment of COVID-19 by ECMO {#sec0015}
=================================================

Based on the entry criteria of EOLIA, ECMO should be considered when meeting one of the following three criteria despite optimization of mechanical ventilation for \<7days (FiO~2~≥0.80, tidal volume of 6 ml/kg predicted body weight, PEEP≥10cmH~2~O) ([@bib0065]): (1) PaO~2~: FiO~2~ \< 50 mmHg for \> 3 hours; (2) PaO~2~: FiO~2~ \< 80 mmHg for \> 6 hours; (3) pH \< 7.25 with PaCO~2~≥60mmHg for \> 6 hours with a respiratory rate increased to 35 breaths per minute, adjusted for plateau pressure≤32 cmH~2~O. Alternatively, after lung protective ventilation (tidal volume 6 ml/kg, PEEP≥10cmH~2~O) was adopted and combined with lung recruitment maneuver, prone position ventilation, and high-frequency oscillation ventilation, patients are still under the condition of pure oxygen inhalation, in these situations, ECMO should be considered for ARDS as rescue therapy when meeting one of the following criteria: (1) PaO~2~/FiO~2~\<100 mmHg; (2) P~(A-a)~O~2~\>600 mmHg; (3) pH \< 7.2 and plateau pressure \>30cmH~2~O with respiratory rate more than 35 breaths per minute; (4) Age\<65 years old; (5) Mechanical ventilation\<7d; (6) Absence of contraindications ([@bib0070]). Besides, for the patients with a harmful potential of ventilator-induced lung injury, lower ventilation and volumes and pressures may lead to hypercapnic acidosis, in this situation, extracorporeal carbon dioxide removal (ECCO2R) can be an important tool by providing direct removal of CO2 from blood ([@bib0065]).

What should we do next? {#sec0020}
=======================

Indeed, many factors could affect the outcomes of ECMO treatment, including the duration of mechanical ventilation, the severity of underlying disease, the experience of trained medical staff, and ECMO equipment. Early evaluation, rapid assembly, and cannulation timely are important. Regardless of the efficacy of ECMO, under the special situation of the SARS-CoV-2 outbreak, we should also pay more attention to the safety of medical staff since they get infected easily when manipulating ECMO. Some approaches, such as intubation, ventilator venting, and sputum suction pose a high risk of infection to medical staff. Therefore, all related staff should be supplied with sufficient protection and be restricted in the independent area. As the pandemic spread, a shortage of ECMO consoles may be another problem to be solved due to a surge of critically ill patients worldwide. Furthermore, trained staff and isolation rooms should be in full preparedness to meet the coming challenges.
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[^2]: ARDS = acute respiratory distress syndrome; CI = confidence interval; ECMO = extracorporeal membrane oxygenation; MERS = middle east respiratory syndrome; RCT = randomized controlled trial; RR = relative risk.

[^3]: ARDS = acute respiratory distress syndrome; COVID-19= coronavirus disease 2019; ECMO = extracorporeal membrane oxygenation; NA = not available; SARS-CoV-2= severe acute respiratory syndrome coronavirus 2.
